mr hamza - Institut Curie - 213777942676

mr hamza

Institut Curie

213777942676

nedroma, Algeria Tlemcen | Algeria

Additional Specialties: DEMANDE

mr hamza - Institut Curie - 213777942676

mr hamza

Introduction

CHER ASSISTANCE ET AMI
JE VOUS TIENS CONNAISSANCE PAR VOTRE INTERMÉDIAIRE QUE J AI UN HÔPITAL DE Passé L INSTITUT CURIE LA Journée 21 octobre 1987, un prés recevoir votre convocation du 8 septembre 1987. et maintenant je soufre beaucoup en Algérie par ce-Que Tous les médecins refusent de me consulter Comme patient. Dans ce cadre je vous teints de m secouriste a visiter institut de Vôtre Pour Que je puisse Prendre consultation de juin au sein de Votre institut. Et aussi j ai rédigé une lettre pour me faciliter de refaire une autre opération sur mon œil
.aussi j ai des rapport qui indique d être opérer au sein de votre hôpital et j aimerai bien de me orienter pour arriver chez vous aussi je vous prie d aider avoir un rendez vous au sein de votre hôpital . Dans l attende d une réponse s favorable. veuillez accepter mes meilleurs salutations.

Mr Khiat Hamza

Primary Affiliation: Institut Curie - nedroma, Algeria Tlemcen , Algeria

Additional Specialties:

Publications

84Publications

4351Reads

1Profile Views

2306PubMed Central Citations

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Cancer Treat Rev 2018 Feb 6;63:144-155. Epub 2017 Dec 6.

Medical Oncology Clinic, Institut Jules Bordet Universite Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.12.002DOI Listing
February 2018
19 Reads
1 Citation
7.590 Impact Factor

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Eur J Cancer 2017 09 22;83:185-193. Epub 2017 Jul 22.

Drug Development Department (DITEP), Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.016DOI Listing
September 2017
164 Reads
1 Citation
5.420 Impact Factor

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.

Br J Cancer 2017 Mar 21;116(7):884-892. Epub 2017 Feb 21.

Northern Centre for Cancer Care, Freeman Hospital, Freeman Road, High Heaton, Newcastle Upon Tyne NE7 7DN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.36DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379148PMC
March 2017
59 Reads
3 Citations
4.840 Impact Factor

Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.

J Nucl Med 2017 02 1;58(2):252-257. Epub 2016 Sep 1.

Service de Médecine Nucléaire, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.116.178749DOI Listing
February 2017
22 Reads
3 Citations
6.160 Impact Factor

[Cell cycle inhibitors in endocrine receptor positive breast cancer].

Bull Cancer 2017 Feb 23;104(2):114-122. Epub 2017 Jan 23.

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.12.005DOI Listing
February 2017
52 Reads
2 Citations
0.640 Impact Factor

Palbociclib and Letrozole in Advanced Breast Cancer.

N Engl J Med 2016 11;375(20):1925-1936

From the Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica (R.S.F., D.J.S.), the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco (H.S.R.), and Pfizer, La Jolla (E.G., D.R.L., S.R.) - all in California; Hospital Gregorio Maranon, Universidad Complutense, Madrid (M.M.); U.S. Oncology Research, The Woodlands, TX (S.J.); Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); British Columbia Cancer Agency, Vancouver, Canada (K.G.); Brustzentrum der Universität München (LMU), Munich, Germany (N.H.); State Budget Medical Institution Republican Clinical Oncology, Ufa, Russia (O.N.L.); All-Ireland Cooperative Oncology Research Group, Dublin (J.M.W.); M.D. Anderson Cancer Center, University of Texas, Houston (S.M.); and Institut Curie, Paris (V.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607303DOI Listing
November 2016
61 Reads
131 Citations
55.873 Impact Factor

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

Br J Clin Pharmacol 2016 May 7;81(5):941-8. Epub 2016 Mar 7.

CNRS, UMR 7292, « Genetics, Immunotherapy, Chemistry and Cancer », Université François Rabelais de Tours, Tours.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834606PMC
May 2016
53 Reads
2 Citations
3.880 Impact Factor

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Int J Cancer 2016 May 6;138(10):2510-21. Epub 2016 Jan 6.

Translational Research Department, Institut Curie, Paris, 75005, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29974DOI Listing
May 2016
50 Reads
4 Citations
5.085 Impact Factor

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

J Clin Oncol 2016 Apr 23;34(10):1034-42. Epub 2015 Nov 23.

Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016PMC
April 2016
115 Reads
34 Citations
18.430 Impact Factor

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Cancer Chemother Pharmacol 2016 Feb 16;77(2):385-92. Epub 2016 Jan 16.

Institut Claudius-Regaud, IUCT-O, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2953-yDOI Listing
February 2016
99 Reads
3 Citations
2.770 Impact Factor

New approaches for improving outcomes in breast cancer in Europe.

Breast 2015 Aug 31;24(4):321-30. Epub 2015 Mar 31.

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.03.001DOI Listing
August 2015
20 Reads
12 Citations
2.381 Impact Factor

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.

J Clin Oncol 2014 Sep 14;32(25):2750-7. Epub 2014 Jul 14.

Véronique Diéras, Institut Curie, Paris, France; Nadia Harbeck, University of Munich, Munich, Germany; G. Thomas Budd, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH; Joel K. Greenson, University of Michigan, Ann Arbor, MI; Ellie A. Guardino, Meghna Samant, Nataliya Chernyukhin, and Melanie C. Smitt, Genentech, South San Francisco, CA; and Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.4999DOI Listing
September 2014
38 Reads
8 Citations
18.430 Impact Factor

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Target Oncol 2014 Jun 14;9(2):111-22. Epub 2013 Jul 14.

Department of Clinical Research, Institut Curie, Paris, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-013-0287-4DOI Listing
June 2014
36 Reads
6 Citations
3.460 Impact Factor

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

J Clin Oncol 2014 May 14;32(14):1437-44. Epub 2014 Apr 14.

Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Reshma L. Mahtani, Sylvester Comprehensive Cancer Center, Miami, FL; Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL; Liang Fang, Glenn Michelson, Genentech, South San Francisco, CA; Howard A. Burris, Sarah Cannon Research Institute, Nashville, TN; Véronique Diéras, Institut Curie, Paris; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Nadia Harbeck, Interdisciplinary Breast Cancer, University of Cologne, Cologne; Nadia Harbeck, Breast Cancer University of Munich, Germany; Luca Gianni, San Raffaele Hospital, Milan; Diana Crivellari, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Italy; Sanne L. de Haas, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.6590DOI Listing
May 2014
61 Reads
18 Citations
18.430 Impact Factor

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Clin Cancer Res 2014 Jan 4;20(2):456-68. Epub 2013 Oct 4.

Authors' Affiliations: Research Oncology, Departments of Biostatistics, Product Development Oncology, and Translational Oncology, Genentech, Inc., South San Francisco, California; Indiana University Simon Cancer Center, Indianapolis, Indiana; Institute Gustave Roussy, Villejuif; Department of Medical Oncology, Institut Curie, Paris, France; Sarah Cannon Research Institute, Nashville, Tennessee; Loyola University Medical Center, Maywood, Illinois; University of Munich, Munich, Germany; and Division of Medical Oncology, Centro di Riferimento Oncologico, Instituto Nazionale Tumori Aviano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0358DOI Listing
January 2014
132 Reads
40 Citations
8.722 Impact Factor

Brain metastases from HER2-positive breast cancer - authors' reply.

Lancet Oncol 2013 Jan;14(1):e3-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(12)70555-7DOI Listing
January 2013
13 Reads
1 Citation
24.690 Impact Factor

Trastuzumab emtansine for HER2-positive advanced breast cancer.

N Engl J Med 2012 Nov 1;367(19):1783-91. Epub 2012 Oct 1.

Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1209124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125250PMC
November 2012
72 Reads
482 Citations
55.873 Impact Factor

Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial.

Radiother Oncol 2012 Jan 8;102(1):82-8. Epub 2011 Sep 8.

Department of Radiation Oncology, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2011.08.017DOI Listing
January 2012
3 Reads
4 Citations
4.363 Impact Factor

Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients.

Int J Radiat Oncol Biol Phys 2011 Nov 6;81(3):631-6. Epub 2010 Oct 6.

Department of Radiation Oncology, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2010.06.057DOI Listing
November 2011
11 Reads
11 Citations
4.260 Impact Factor

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Eur J Cancer 2011 Jul 7;47(10):1468-75. Epub 2011 Apr 7.

Department of Medical Oncology, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.03.016DOI Listing
July 2011
42 Reads
14 Citations
5.420 Impact Factor

[Survival of breast cancers patients with meningeal carcinoma].

Bull Cancer 2011 Apr;98(4):391-8

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1340DOI Listing
April 2011
19 Reads
0.640 Impact Factor

[Brain metastasis of breast tumors and blood brain barrier].

Bull Cancer 2011 Apr;98(4):385-9

Institut Curie, département d'oncologie médicale, unité d'investigation clinique, 25, rue d'Ulm, 75248 Paris Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1336DOI Listing
April 2011
15 Reads
2 Citations
0.640 Impact Factor

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

Eur J Cancer 2010 Dec 6;46(18):3243-50. Epub 2010 Sep 6.

Department of Medical Oncology, Beaujon University Hospital, Paris 7, AP-HP, Clichy, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2010.08.001DOI Listing
December 2010
96 Reads
28 Citations
5.420 Impact Factor

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Breast Cancer Res Treat 2010 Jul 2;122(1):181-8. Epub 2010 Apr 2.

Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, University Hospital, Via del Pozzo 71, 41100 Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-0866-3DOI Listing
July 2010
18 Reads
28 Citations
3.940 Impact Factor

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Target Oncol 2010 Mar 2;5(1):65-72. Epub 2010 Apr 2.

Département d'oncologie médicale, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11523-010-0137-6
Publisher Site
http://dx.doi.org/10.1007/s11523-010-0137-6DOI Listing
March 2010
43 Reads
6 Citations
3.460 Impact Factor

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.

J Neurooncol 2009 Jul 25;93(3):379-84. Epub 2009 Jan 25.

Department of Radiation Oncology, Institut Curie, Paris, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-008-9791-2
Publisher Site
http://dx.doi.org/10.1007/s11060-008-9791-2DOI Listing
July 2009
73 Reads
6 Citations
3.070 Impact Factor

Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse.

Clin Exp Metastasis 2008 7;25(8):871-5. Epub 2008 Nov 7.

Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-008-9203-1DOI Listing
January 2009
79 Reads
5 Citations
3.491 Impact Factor

A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.

J Cancer Res Clin Oncol 2008 Feb 17;134(2):125-35. Epub 2007 Jul 17.

Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-007-0259-0DOI Listing
February 2008
28 Reads
2 Citations
3.081 Impact Factor

[Phase I cancer trials methodology].

Bull Cancer 2007 Nov;94(11):943-51

Service inter-hospitalier de cancérologie, Hôpital Beaujon, 100, boulevard du général Leclerc, 92110 Clichy.

View Article

Download full-text PDF

Source
November 2007
31 Reads
0.640 Impact Factor

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Clin Cancer Res 2007 Jul;13(13):3989-98

U612 Institut National de la Sante et de la Recherche Medicale, Pharmacologie Préclinique Antitumorale, Paris Anatomie et Cytologie Pathologique, Hôpital Trousseau, Tours, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0078DOI Listing
July 2007
61 Reads
125 Citations
8.722 Impact Factor

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Bull Cancer 2007 Mar;94(3):259-66

Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05.

View Article

Download full-text PDF

Source
March 2007
56 Reads
4 Citations
0.640 Impact Factor

Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.

Eur J Cancer 2006 Sep 8;42(14):2286-95. Epub 2006 Aug 8.

Department of Radiotherapy, Institut Curie, 26 Rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2006.03.026DOI Listing
September 2006
20 Reads
10 Citations
5.420 Impact Factor

[Oxaliplatin and ovarian cancer].

Bull Cancer 2006 Feb;93 Suppl 1:S35-9

Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05.

View Article

Download full-text PDF

Source
February 2006
4 Reads
3 Citations
0.640 Impact Factor

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.

Eur J Cancer 2005 Aug;41(12):1739-45

Department of Medicine and Department of Clinical Biochemistry, Institut Gustave-Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2005.04.029DOI Listing
August 2005
30 Reads
11 Citations
5.420 Impact Factor

[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].

Bull Cancer 2004 Dec;91(12):917-27

Unité de pharmacologie, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
December 2004
42 Reads
0.640 Impact Factor

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study.

Cancer Chemother Pharmacol 2004 Jun 7;53(6):489-95. Epub 2004 Feb 7.

Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0762-9DOI Listing
June 2004
73 Reads
3 Citations
2.770 Impact Factor

[Update on docetaxel and breast cancer].

Bull Cancer 2004 May;91(5):409-17

Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75005 Paris.

View Article

Download full-text PDF

Source
May 2004
25 Reads
0.640 Impact Factor

[Targeting epidermal growth factor receptor in cancer of the breast].

Bull Cancer 2003 Nov;90 Spec No:S257-62

Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75005 Paris.

View Article

Download full-text PDF

Source
November 2003
5 Reads
0.640 Impact Factor

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Invest New Drugs 2003 Aug;21(3):347-52

Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, Vienna, Austria.

View Article

Download full-text PDF

Source
August 2003
16 Reads
5 Citations
2.920 Impact Factor

Chemotherapy for metastatic breast cancer-report of a European expert panel.

Lancet Oncol 2002 Dec;3(12):719-27

Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
December 2002
4 Reads
14 Citations
24.690 Impact Factor

Top co-authors

Veronique Dieras
Veronique Dieras

Institut Curie

54
Thomas Bachelot
Thomas Bachelot

Université de Lyon

13
Mario Campone
Mario Campone

Institut de Cancérologie de l'Ouest

10
Brigitte Sigal-Zafrani
Brigitte Sigal-Zafrani

Paris V University

10
Alain Fourquet
Alain Fourquet

Department of Clinical Hematology

9
Marta Jimenez
Marta Jimenez

Environmental and Occupational Health Sciences Institute

8
Valerie Laurence
Valerie Laurence

St. James's University Hospital

8